A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Clinical Pharmacology & Therapeutics · 2025-05 · 117 (5) · 1194-1208
DOI: 10.1002/cpt.3567 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 31.01.2025. Verfasst von Teresa T Ho und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic, Fluorouracil, Dihydropyrimidine Dehydrogenase Deficiency. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The safety of systemic fluoropyrimidines (e.g., 5‐fluorouracil, capecitabine) is impacted by germline genetic variants in DPYD, which encodes the dihydropyrimidine dehydrogenase (DPD) enzyme that functions as the rate‐limiting step in the catabolism of this drug class. Genetic testing to identify those with DPD deficiency can help mitigate the risk of severe and life‐threatening fluoropyrimidine‐induced toxicities. Globally, the integration of DPYD genetic testing into patient care has varied greatly, ranging from being required as the standard of care in some countries to limited clinical use in others. Thus, implementation strategies have evolved differently across health systems and countries. The primary objective of this tutorial is to provide practical considerations and best practice recommendations for the implementation of DPYD ‐guided systemic fluoropyrimidine dosing. We adapted the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework to cover topics including the clinical evidence supporting DPYD genotyping to guide fluoropyrimidine therapy, regulatory guidance for DPYD genotyping, key stakeholder engagement, logistics for DPYD genotyping, development of point‐of‐care clinical decision support tools, and considerations for the creation of sustainable and scalable DPYD genotype‐integrated workflows. This guide also describes approaches to counseling patients about DPYD testing and result disclosure, along with examples of patient and provider educational resources. Together, DPYD testing and clinical practice integration aim to promote safe prescribing of fluoropyrimidine therapy and decrease the risk of severe and life‐threatening fluoropyrimidine toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
- Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia, USA.
- MedStar Health, Columbia, Maryland, USA.
- Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
- Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Teresa T Ho, D Max Smith, Emily J Cicali, Daniel L Hertz, Jai N Patel, Stuart A Scott, Sandra M Swain, Sony Tuteja, J Kevin Hicks
Zitieren
APA
Ho, T. T., Smith, D. M., Aquilante, C. L., Cicali, E. J., El Rouby, N., Hertz, D. L., Imanirad, I., Patel, J. N., Scott, S. A., Swain, S. M., Tuteja, S., Hicks, J. K., & Pharmacogenomics Global Research Network Publication Committee (2025). A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clinical Pharmacology & Therapeutics, 117(5), 1194-1208. https://doi.org/10.1002/cpt.3567
Vancouver
Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, et al. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clinical Pharmacology & Therapeutics. 2025;117(5):1194-1208. doi:10.1002/cpt.3567
BibTeX
@article{Ho2025,
author = {Ho, Teresa T and Smith, D Max and Aquilante, Christina L and Cicali, Emily J and El Rouby, Nihal and Hertz, Daniel L and Imanirad, Iman and Patel, Jai N and Scott, Stuart A and Swain, Sandra M and Tuteja, Sony and Hicks, J Kevin and Pharmacogenomics Global Research Network Publication Committee, Pharmacogenomics Global Research Network Publication Committee},
title = {A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {5},
pages = {1194--1208},
doi = {10.1002/cpt.3567}
}
EUVIMED